NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Non Small Cell Lung Cancer Interventions: Drug: efineptakin alfa; Drug: Atezolizumab Sponsors: NeoImmuneTech; Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials